Pharma firm Cadila Healthcare has said that it has entered into a strategic collaboration with Sweden-based Karo Bio to discover and develop drug for treatment of inflammatory diseases. Cadila has signed a three-year research agreement in the area of drug discovery for selective glucocorticoid receptor (GR) modulators for the treatment of rheumatoid arthritis, psoriasis and asthma, the company informed the BSE. "One of the key research areas of focus at our Zydus Research Centre is to develop novel GR modulators that are devoid of side effects," Zydus Cadila CMD Pankaj R Patel said.
Every time an offender stealthily leaves India to take refuge in another country, the Government of India starts all over again with its strategy of bringing him back to the nation to make him stan More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More